July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Plasmacytoid Dendritic Cells Inhibit Vascular Endothelial Cell Proliferation and Differentiation through the Angiostatic Molecule Platelet Factor-4
Author Affiliations & Notes
  • Deshea L Harris
    Center for Translational Ocular Immunology and Department of Ophthalmology, Tufts Medical Center and Tufts University School of Medicine, Boston, Massachusetts, United States
  • Arsia Jamali
    Center for Translational Ocular Immunology and Department of Ophthalmology, Tufts Medical Center and Tufts University School of Medicine, Boston, Massachusetts, United States
  • Abdo Abou-Slaybi
    Center for Translational Ocular Immunology and Department of Ophthalmology, Tufts Medical Center and Tufts University School of Medicine, Boston, Massachusetts, United States
  • Pedram Hamrah
    Center for Translational Ocular Immunology and Department of Ophthalmology, Tufts Medical Center and Tufts University School of Medicine, Boston, Massachusetts, United States
    Cornea Service, New England Eye Center, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Deshea Harris, None; Arsia Jamali, Tufts Medical Center (P); Abdo Abou-Slaybi, None; Pedram Hamrah, Tufts Medical Center (P)
  • Footnotes
    Support  NIH R01-EY026963 (PH), NIH Grant EY026963 (PH), Tufts Medical Center Institutional Support
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 951. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Deshea L Harris, Arsia Jamali, Abdo Abou-Slaybi, Pedram Hamrah; Plasmacytoid Dendritic Cells Inhibit Vascular Endothelial Cell Proliferation and Differentiation through the Angiostatic Molecule Platelet Factor-4. Invest. Ophthalmol. Vis. Sci. 2019;60(9):951.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : We have recently demonstrated that corneal plasmacytoid dendritic cells (pDCs) contribute to the preservation of corneal avascularity. The aim of this study is to analyze the secretion of angiostatic molecules by pDCs and their effect on vascular endothelial cell proliferation and differentiation in vitro.

Methods : pDC-eGFPxRAGKO mice (in which only pDCs express GFP) were injected subcutaneously with B16 Flt3-L melanoma tumor cells. Splenic pDCs were isolated by sorting for GFP at day 10. To study endothelial cell proliferation and tube formation, pDCs were cultured in transwell inserts (TW) with human umbilical vein endothelial cells (HUVECs) with and without underlying Matrigel-coated well for 1 and 5 days, respectively. Real-time (RT) qPCR of pDCs for endostatin (ES), thrombospondin (TSP)-1 and -2, metalloproteinase inhibitor 3 (TIMP-3) and platelet factor 4 (PF-4) were performed. Proliferation using a hemocytometer and differentiation of HUVECs by formation of tube-like structures were evaluated after addition of blocking antibodies for TSP-1 or PF-4 or their isotype controls. The central area of each well was monitored and total length of all tubes measured using Angiogenesis Analyzer for ImageJ.

Results : RT-qPCR of pDCs in TW showed increased mRNA expression from day 1 to day 5 of PF-4 (7.27 fold; p<0.05) and TSP-1 (2.74 fold; p<0.05). ES mRNA showed no significant change, while TSP-2 and TIMP-3 mRNA levels decreased, although only significantly for TIMP-3 (2 fold; p<0.001). pDCs decreased proliferation of HUVECs, but the addition of PF-4 blocking antibody abolished this effect completely (p<0.05). No significant difference to controls was noted for blocking antibody to TSP-1. Addition of pDCs to HUVECs on Matrigel inhibited formation of tube-like structures as compared to controls without pDCs. Addition of PF-4 blocking antibody ameliorated the effect of decreased tube formation by pDCs significantly (p<0.05), restoring total tube length to control levels. However, blocking antibody to TSP-1 showed no significant difference to controls.

Conclusions : Our study demonstrates that the angiostatic effect of pDCs on the reduction of vascular endothelial cell proliferation and differentiation in vitro is mediated by PF-4. Cell-based therapy using pDCs may be considered as potential treatment option for corneal angiogenesis.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×